Overview

* Bioventus ( BVS ) Q3 revenue of $138.7 mln beats analyst expectations, driven by organic growth

* Adjusted EPS for Q3 increases 200% yr/yr, exceeding analyst estimates

* Company reaffirms 2025 revenue, Adjusted EBITDA, and Non-GAAP EPS guidance

Outlook

* Bioventus ( BVS ) reaffirms 2025 net sales guidance of $560 mln to $570 mln

* Company expects 2025 Adjusted EBITDA of $112 mln to $116 mln

* Bioventus ( BVS ) projects 2025 Non-GAAP EPS of $0.64 to $0.68

Result Drivers

* ORGANIC GROWTH - Q3 organic revenue increased 8% driven by above-market growth across all three areas of the company's portfolio

* DIVESTITURE IMPACT - Reported revenue declined 0.2% due to the prior-year divestiture of the Advanced Rehabilitation Business

* PROFITABILITY IMPROVEMENT - Non-GAAP EPS increased 200% driven by improved operating profitability and lower interest expense

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Sales Beat $138.70 $138.20

mln mln (3

Analysts

)

Q3 Beat $0.15 $0.11 (2

Adjusted Analysts

EPS )

Q3 $26.60

Adjusted mln

EBITDA

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

* Wall Street's median 12-month price target for Bioventus Inc ( BVS ) is $15.00, about 56.3% above its November 3 closing price of $6.56

* The stock recently traded at 8 times the next 12-month earnings vs. a P/E of 8 three months ago

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)